REDHILL BIOPHAR/S (NASDAQ:RDHL) Expected to Post Quarterly Sales of $1.46 Million

Analysts expect that REDHILL BIOPHAR/S (NASDAQ:RDHL) will post sales of $1.46 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for REDHILL BIOPHAR/S’s earnings, with the lowest sales estimate coming in at $1.26 million and the highest estimate coming in at $1.66 million. REDHILL BIOPHAR/S posted sales of $1.36 million in the same quarter last year, which suggests a positive year-over-year growth rate of 7.4%. The business is scheduled to report its next earnings report on Tuesday, February 25th.

On average, analysts expect that REDHILL BIOPHAR/S will report full year sales of $6.44 million for the current year, with estimates ranging from $5.96 million to $7.00 million. For the next financial year, analysts forecast that the firm will post sales of $37.64 million, with estimates ranging from $20.26 million to $49.11 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow REDHILL BIOPHAR/S.

A number of analysts have recently commented on RDHL shares. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of REDHILL BIOPHAR/S in a research report on Wednesday, November 20th. Zacks Investment Research cut shares of REDHILL BIOPHAR/S from a “buy” rating to a “hold” rating in a report on Tuesday, November 26th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $18.00.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Boston Partners acquired a new stake in shares of REDHILL BIOPHAR/S in the third quarter valued at about $190,000. ETF Managers Group LLC grew its stake in REDHILL BIOPHAR/S by 10.7% in the second quarter. ETF Managers Group LLC now owns 46,255 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 4,453 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of REDHILL BIOPHAR/S during the 2nd quarter worth approximately $384,000. CLARET ASSET MANAGEMENT Corp increased its position in shares of REDHILL BIOPHAR/S by 22.1% during the 3rd quarter. CLARET ASSET MANAGEMENT Corp now owns 75,102 shares of the biotechnology company’s stock worth $529,000 after purchasing an additional 13,600 shares during the last quarter. Finally, Disciplined Growth Investors Inc. MN increased its position in shares of REDHILL BIOPHAR/S by 0.4% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 1,145,014 shares of the biotechnology company’s stock worth $8,061,000 after purchasing an additional 4,550 shares during the last quarter. Institutional investors own 37.00% of the company’s stock.

Shares of RDHL traded down $0.24 during mid-day trading on Friday, hitting $6.20. 183,159 shares of the company’s stock were exchanged, compared to its average volume of 123,554. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.22 and a quick ratio of 2.08. REDHILL BIOPHAR/S has a 52 week low of $5.13 and a 52 week high of $9.20. The company has a market cap of $136.00 million, a PE ratio of -3.65 and a beta of 1.33. The company has a 50-day simple moving average of $6.49 and a 200 day simple moving average of $6.98.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Further Reading: Why Invest in Dividend Achievers?

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.